BR112015013984A2 - métodos para o tratamento de prurido - Google Patents

métodos para o tratamento de prurido

Info

Publication number
BR112015013984A2
BR112015013984A2 BR112015013984A BR112015013984A BR112015013984A2 BR 112015013984 A2 BR112015013984 A2 BR 112015013984A2 BR 112015013984 A BR112015013984 A BR 112015013984A BR 112015013984 A BR112015013984 A BR 112015013984A BR 112015013984 A2 BR112015013984 A2 BR 112015013984A2
Authority
BR
Brazil
Prior art keywords
methods
treating itching
treating
itching
treating pruritus
Prior art date
Application number
BR112015013984A
Other languages
English (en)
Portuguese (pt)
Inventor
Sciascia Thomas
Original Assignee
Trevi Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/715,625 external-priority patent/US8637538B1/en
Application filed by Trevi Therapeutics Inc filed Critical Trevi Therapeutics Inc
Publication of BR112015013984A2 publication Critical patent/BR112015013984A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
BR112015013984A 2012-12-14 2013-12-13 métodos para o tratamento de prurido BR112015013984A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261737488P 2012-12-14 2012-12-14
US13/715,625 US8637538B1 (en) 2012-12-14 2012-12-14 Methods for treatment of pruritis
PCT/US2013/075096 WO2014093871A1 (en) 2012-12-14 2013-12-13 Methods for treating pruritus

Publications (1)

Publication Number Publication Date
BR112015013984A2 true BR112015013984A2 (pt) 2017-07-11

Family

ID=50935003

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015013984A BR112015013984A2 (pt) 2012-12-14 2013-12-13 métodos para o tratamento de prurido

Country Status (13)

Country Link
EP (1) EP2931279B1 (cg-RX-API-DMAC10.html)
JP (4) JP2016506398A (cg-RX-API-DMAC10.html)
KR (3) KR20150093702A (cg-RX-API-DMAC10.html)
CN (2) CN110585209A (cg-RX-API-DMAC10.html)
AU (2) AU2013359017B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015013984A2 (cg-RX-API-DMAC10.html)
CA (1) CA2892393C (cg-RX-API-DMAC10.html)
ES (1) ES2984559T3 (cg-RX-API-DMAC10.html)
MX (1) MX2015007518A (cg-RX-API-DMAC10.html)
NZ (1) NZ708371A (cg-RX-API-DMAC10.html)
RU (1) RU2015128265A (cg-RX-API-DMAC10.html)
WO (1) WO2014093871A1 (cg-RX-API-DMAC10.html)
ZA (2) ZA201504229B (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明(cyclopamine)類似物類
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
JP2016506398A (ja) * 2012-12-14 2016-03-03 トレビ セラピューティクス インコーポレイテッド そう痒の処置法
WO2015192071A1 (en) * 2014-06-13 2015-12-17 Trevi Therapeutics, Inc. Methods for treating pruritus
BR112017026103B1 (pt) 2015-06-04 2023-10-03 Sol-Gel Technologies Ltd Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos
TW201725041A (zh) * 2016-01-04 2017-07-16 懷特生技新藥股份有限公司 治療皮膚癢之醫藥組合物
CN105560202B (zh) * 2016-03-11 2019-05-24 广州玻思韬控释药业有限公司 一种盐酸纳布啡凝胶骨架缓释片的制备方法及应用
CA3017374A1 (en) * 2016-03-21 2017-09-28 Trevi Therapeutics, Inc. Treatment of uremic pruritus
WO2018081273A1 (en) * 2016-10-25 2018-05-03 Trevi Therapeutics, Inc. Treatment of prurigo nodularis
KR102329377B1 (ko) * 2017-02-03 2021-11-19 가부시키가이샤 도요 신야쿠 고형 제제
CN118512451A (zh) * 2018-07-23 2024-08-20 特雷维治疗股份有限公司 慢性咳嗽、呼吸急促和呼吸困难的治疗
IL294601A (en) 2020-01-10 2022-09-01 Trevi Therapeutics Inc Methods of administration of nalbuphine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1535687A (zh) * 1996-11-25 2004-10-13 ������������ʽ���� 止痒药物
US20030054030A1 (en) * 2001-09-13 2003-03-20 Gary Gordon Method and compositions for the treatment of pruritus
US6703398B2 (en) * 2001-11-26 2004-03-09 Oliver Yoa-Pu Hu Orally administered analgesic compositions containing nalbuphine
LT2425821T (lt) * 2002-04-05 2017-07-25 Euro-Celtique S.A. Farmacinis preparatas, turintis oksikodono ir naloksono
CA2566217A1 (en) * 2004-06-03 2005-12-15 Jonathan J. Burbaum Pharmaceutical compositions for the treatment of pruritus
CA2620224C (en) 2005-08-24 2015-11-24 Penwest Pharmaceuticals Company Sustained release formulations of nalbuphine
US8394812B2 (en) 2005-08-24 2013-03-12 Penwest Pharmaceuticals Co. Sustained release formulations of nalbuphine
FR2963889B1 (fr) * 2010-08-20 2013-04-12 Debregeas Et Associes Pharma Formulations a base de nalbuphine et leurs utilisations
JP2016506398A (ja) * 2012-12-14 2016-03-03 トレビ セラピューティクス インコーポレイテッド そう痒の処置法

Also Published As

Publication number Publication date
HK1215541A1 (en) 2016-09-02
ZA201906339B (en) 2021-07-28
AU2013359017B2 (en) 2018-05-10
CA2892393C (en) 2021-06-08
MX2015007518A (es) 2016-03-01
CN110585209A (zh) 2019-12-20
JP7072280B2 (ja) 2022-05-20
NZ708371A (en) 2020-05-29
AU2018214098A1 (en) 2018-08-30
KR20210050585A (ko) 2021-05-07
JP6823857B2 (ja) 2021-02-03
RU2015128265A (ru) 2017-01-25
AU2018214098B2 (en) 2019-04-18
JP2021020947A (ja) 2021-02-18
WO2014093871A1 (en) 2014-06-19
CN104981246A (zh) 2015-10-14
ZA201504229B (en) 2021-07-28
JP2016506398A (ja) 2016-03-03
EP2931279B1 (en) 2024-03-20
JP2019131588A (ja) 2019-08-08
KR20220044385A (ko) 2022-04-07
CA2892393A1 (en) 2014-06-19
AU2013359017A1 (en) 2015-06-11
ES2984559T3 (es) 2024-10-29
EP2931279A4 (en) 2016-05-11
KR20150093702A (ko) 2015-08-18
JP2022105095A (ja) 2022-07-12
EP2931279A1 (en) 2015-10-21

Similar Documents

Publication Publication Date Title
MX2014010481A (es) Nuevas composiciones para el tratamiento de la esclerosis lateral amiotrofica.
MX2015007518A (es) Metodos para tratar el prurito.
MX365614B (es) Composiciones utiles para tratar trastornos relacionados con kit.
BR112015028870A2 (pt) estruturas fibrosas hidroentrelaçadas
MX2015012411A (es) Sales de aminas cuaternarias ambientalmente amigables y su uso como estabilizadores de arcilla temporales y/o permanentes y métodos para elaborarlas y utilizarlas.
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
CO7111287A2 (es) Composiciones plaguicidas y procesos relacionados
BR112014027925A2 (pt) recipientes flexíveis
UY34145A (es) Compuestos inhibidores de metaloenzimas
UY34550A (es) Bencilpirazoles sustituidos
UY34763A (es) Inhibidores de la agregación plaquetaria
UY4211Q (es) Pizarra para marcadores
UY34817A (es) Tienopirimidinas
UY33936A (es) Derivados de fluoro-piridinona útiles como agentesantibacterianos.
IN2014DN01809A (cg-RX-API-DMAC10.html)
CR20140306A (es) Fluormetil -5,6-dihidro-4h-[1,3] oxazinas
BR112014003806A2 (pt) polímeros de adsorção de sujeira
TR201907380T4 (tr) Bitkiler için gelişmiş güvenliğe sahip olan herbisidal bileşim.
UY34355A (es) Composición ecológica para curtido
PH12015502665A1 (en) Improvements in or relating to organic compounds
BR112015011798A2 (pt) métodos e composições para tratar doenças neurodegenerativas
EP3344893A4 (en) WEAR OPTIMIZED STOCK DESIGN
BR112015019924A2 (pt) métodos e composições para tratar leucemia
BR112013026964A2 (pt) composição de polímero dispersível em água
BR112013027221A2 (pt) composição vaginal com base alquil poliglicosídeos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]